These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 3489541)

  • 1. The functional loss of human natural killer cell activity induced by K562 is reversible via an interleukin-2-dependent mechanism.
    Abrams SI; Brahmi Z
    Cell Immunol; 1986 Sep; 101(2):558-70. PubMed ID: 3489541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target cell-directed inactivation and IL-2-dependent reactivation of LAK cells.
    Xiao J; Brahmi Z
    Cell Immunol; 1989 Sep; 122(2):295-306. PubMed ID: 2788512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for an early calcium-independent event in the activation of the human natural killer cell cytolytic mechanism.
    Brahmi Z; Bray RA; Abrams SI
    J Immunol; 1985 Dec; 135(6):4108-13. PubMed ID: 3864859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target cell directed NK inactivation. Concomitant loss of NK and antibody-dependent cellular cytotoxicity activities.
    Abrams SI; Brahmi Z
    J Immunol; 1988 Mar; 140(6):2090-5. PubMed ID: 3279127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
    Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
    Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Killer cell recruitment and renewal capacity of purified cytolytic and noncytolytic human peripheral blood natural killer cell subsets.
    Lebow LT; Jewett A; Bonavida B
    J Immunol; 1993 Jan; 150(1):320-9. PubMed ID: 8417130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
    van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
    J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irreversible cancer cell-induced functional anergy and apoptosis in resting and activated NK cells.
    Cavalcanti M; Jewett A; Bonavida B
    Int J Oncol; 1999 Feb; 14(2):361-6. PubMed ID: 9917514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant effect of interferon on natural killer activity and tumor cell sensitivity to lysis in hairy cell leukemia.
    Lahat N; Aghai E; Kotler A; Kinarty A; Sobel E; Gruener N; Froom P
    Blood; 1988 Apr; 71(4):1141-3. PubMed ID: 3258536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in gene expression associated with IFN-beta and IL-2-induced augmentation of human natural killer cell function.
    Kornbluth J; Hoover RG
    J Immunol; 1988 Nov; 141(9):3234-40. PubMed ID: 3049820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells.
    Frey JR; Kamber M; Peck R
    Lymphokine Res; 1987; 6(3):215-27. PubMed ID: 3114569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lytic activity of IL-2 and IL-12 stimulated NK cells against HOS osteosarcoma cell line.
    Mariani E; Tarozzi A; Meneghetti A; Tadolini M; Facchini A
    Boll Soc Ital Biol Sper; 1996; 72(1-2):21-7. PubMed ID: 8868111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of soluble cytotoxic factors generated by mycoplasma-contaminated targets to natural killer cell-mediated killing.
    Hommel-Berrey GA; Brahmi Z
    Hum Immunol; 1987 Sep; 20(1):33-46. PubMed ID: 3679901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural cytotoxicity of human blood lymphocytes and monocytes and their cytotoxic factors: effect of interferon on target cell susceptibility.
    Uchida A; Vánky F; Klein E
    J Natl Cancer Inst; 1985 Nov; 75(5):849-57. PubMed ID: 2414505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of natural killer cytotoxicity by Escherichia coli-derived human interferon gamma.
    Platsoucas CD
    Scand J Immunol; 1986 Jul; 24(1):93-108. PubMed ID: 3088722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural-killer-stimulatory effect of combined low-dose interleukin-2 and interferon beta in hairy-cell leukemia patients.
    Liberati AM; De Angelis V; Fizzotti M; Schippa M; Cecchini M; Adiuto D; Di Clemente F; Palmisano L; Micozzi E; Zuccaccia M
    Cancer Immunol Immunother; 1994 May; 38(5):323-31. PubMed ID: 7512888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro modulation of human natural killer cell activity by interferon: generation of adherent suppressor cells.
    Uchida A; Yanagawa E; Kokoschka EM; Micksche M; Koren HS
    Br J Cancer; 1984 Oct; 50(4):483-92. PubMed ID: 6237664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells.
    Jewett A; Bonavida B
    J Clin Immunol; 1995 Jan; 15(1):35-44. PubMed ID: 7759599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.